SB 84 amends Louisiana insurance law to require coverage of prostate cancer screening—specifically digital rectal exams and prostate‑specific antigen (PSA) testing—for men aged 50 and older, and to extend coverage for men ages 40–49 when consistent with the National Comprehensive Cancer Network (NCCN) guidelines. The bill also bars any patient cost-sharing (deductibles, coinsurance, copays, or similar out-of-pocket charges) for screenings that the statute requires.
The change hits insurers and plan administrators directly: they must update policy documents and claims-processing rules to cover the specified screenings without cost-sharing. The law applies to new policies issued on or after January 1, 2027, and forces existing policies to conform on renewal but no later than January 1, 2028.
At a Glance
What It Does
The bill explicitly lists digital rectal examination and PSA testing as covered prostate cancer screening services and ties coverage for 40–49 year‑olds to the most recently published NCCN guidelines. It prohibits any deductible, coinsurance, copayment, or similar out-of-pocket expense for screenings the statute requires.
Who It Affects
Insurers and regulated health plans that issue policies in Louisiana must change benefit language and claims adjudication; clinicians and labs will see preventive-screening claims processed without patient cost-sharing. Self‑funded ERISA plans are likely unaffected by the state mandate (see fine print).
Why It Matters
This shifts the financial barrier for prostate screening onto payers for mandated services, may increase screening uptake among insured men, and locks coverage decisions for ages 40–49 to an external clinical standard (NCCN), which can evolve over time.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 84 creates two linked obligations for state‑regulated health coverage. First, it makes digital rectal exam (DRE) and prostate‑specific antigen (PSA) testing standard covered benefits for men 50 and older.
Second, it conditions coverage for men aged 40–49 on whether those services are recommended by the most recent NCCN guidance; if NCCN recommends screening for a man in that age band, the insurer must cover it.
The bill goes beyond coverage and targets the patient financial barrier: it prohibits any cost-sharing for the screenings the statute requires. That means insurers must pay those claims as preventive benefits without applying deductibles, coinsurance, copays, or analogous patient charges.
Providers and billing departments will need to ensure claims are coded and submitted as preventive/screening services to avoid collection attempts.Practical implementation will involve updating plan documents, member communications, and claims systems ahead of the effective dates. For new policies issued on or after January 1, 2027, carriers must incorporate the changes immediately; for existing policies, carriers must conform on the first renewal after that date but no later than January 1, 2028.
Carriers should also track NCCN publications so coverage determinations for 40–49 year‑olds reflect the “most recently published” guidance language in the statute.Although the statute uses broad language—"any health coverage plan delivered or issued for delivery in the state"—it cannot override federal ERISA preemption for self‑funded employer plans. That means many large employer plans that are self‑funded may not be required to change benefits, leaving insured plans (individual and fully insured group products regulated by the state) as the primary universe for compliance.Operationally, labs, primary care, and urology practices should expect a rise in preventive‑coded PSA/DRE claims from insured patients and should coordinate with payers on preauthorization and coding rules.
Insurers should prepare updating preventive-care exclusions, prior‑authorization policies (if any), and provider/ member materials to reflect the no cost-sharing rule and the NCCN‑dependent eligibility for the 40–49 cohort.
The Five Things You Need to Know
The statute explicitly names digital rectal exam (DRE) and PSA testing as covered prostate cancer screening services.
Coverage for men aged 40–49 is limited to situations "in accordance with the most recently published guidelines" from the National Comprehensive Cancer Network (NCCN).
The bill forbids any patient cost-sharing for mandated screenings, including deductibles, coinsurance, copayments, or similar out-of-pocket expenses.
The rules apply to new policies issued on or after January 1, 2027; existing policies must conform at renewal but no later than January 1, 2028.
State coverage mandates generally do not bind self‑funded ERISA plans, so the law will primarily affect insured individual and fully insured group plans regulated in Louisiana.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Mandated coverage for DRE and PSA; NCCN standard for ages 40–49
This amendment requires any health coverage plan issued or delivered in Louisiana to cover prostate cancer detection via digital rectal exam and PSA testing for men 50 and older. For men aged 40–49 the statute narrows coverage to situations that are medically necessary and "in accordance with" the latest NCCN guidance. Practically, insurers must interpret NCCN recommendations and translate them into medical-necessity and coverage policies for the 40–49 cohort, and they must ensure benefit language reflects mandatory coverage for the 50+ cohort.
Prohibition on patient cost-sharing for mandated screenings
This change removes any ambiguity about patient financial responsibility by banning deductibles, coinsurance, copayments, and similar out-of-pocket charges for screenings the statute requires. Insurers will need to adjust claims processing so that mandated prostate screening claims are adjudicated as fully covered preventive services; failure to do so could produce member complaints and regulatory enforcement actions.
Effective dates and phase‑in for existing policies
The bill applies immediately to new policies issued on or after January 1, 2027. Policies in force before that date must conform when they renew, but insurers cannot delay changes beyond January 1, 2028. This creates a 12‑month phase‑in window for legacy contracts and obliges issuers to update policy language, summary plan descriptions, and renewal notices to reflect the new coverage and cost‑sharing rules.
Governor signature and traditional effective date language
The bill becomes effective upon the governor's signature or after lapse of time as provided by the state constitution; if vetoed and reenacted, it takes effect the day after legislative approval. This is standard enactment language and does not modify the statutory applicability dates described in Section 2.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Insured men 50 and older — obtain guaranteed coverage for DRE and PSA screening without any out-of-pocket cost under insured plans, reducing financial barriers to screening.
- At‑risk men aged 40–49 who meet NCCN criteria — if NCCN guidance recommends screening for them, insurers must cover the service and waive cost-sharing, potentially enabling earlier detection in higher‑risk individuals.
- Primary care and urology providers — fewer billing disputes and greater patient acceptance of screening when cost barriers are removed, which may increase preventive visit volume and screening uptake.
Who Bears the Cost
- State‑regulated insurers and fully insured group plans — will absorb the expense of preventive prostate screenings previously subject to cost-sharing and must update administration and claims systems.
- Employers buying fully insured coverage — may face higher premiums over time as carriers price in the added preventive coverage and administrative costs.
- Health plan administrators and compliance teams — must track NCCN revisions, revise medical‑necessity policies, retrain staff, and update member communications and claims rules before the 2027/2028 deadlines.
Key Issues
The Core Tension
The bill balances two legitimate goals—expanding access to potentially life‑saving prostate cancer screening and limiting patient financial barriers—against the realities of insurer cost exposure, ERISA preemption, and the operational burden of tethering coverage to an evolving external clinical standard (NCCN). Expanding no‑cost screening advances prevention but shifts costs and administrative complexity onto payers and plan administrators, while leaving self‑funded plans outside the mandate produces uneven access.
Two implementation puzzles stand out. First, the bill ties coverage for the 40–49 age group to the "most recently published" NCCN guidelines.
That creates a moving target: plans must monitor NCCN updates and quickly operationalize changes, but the statute does not prescribe a notice period or specify whether insurers may apply a lag between NCCN publication and plan coverage. This can produce timing mismatches (e.g., NCCN updates mid‑plan year) and disputes over whether a particular screening is covered at the time of service.
Second, the statute's scope is limited by federal ERISA law. State insurance mandates generally bind insured products regulated by the state, but they cannot compel changes to self‑funded employer plans subject to ERISA.
The bill therefore will not create universal coverage across all employer-sponsored plans, producing uneven access depending on plan type. Additionally, the prohibition on cost-sharing applies only to the screening services required by the statute; it does not explicitly cover follow‑up diagnostic testing, imaging, or treatment triggered by a positive screening result, leaving room for patient cost exposure after an abnormal screen.
Operationally, carriers and providers must resolve billing and coding questions (how to mark a PSA as preventive vs diagnostic), reconcile prior authorization practices with a no cost‑sharing rule, and decide how to incorporate NCCN nuance such as risk‑stratified screening. Regulators will need clear guidance and oversight procedures to handle member complaints, and actuaries will need to quantify expected utilization and premium impacts—tasks the bill assigns implicitly but does not fund or timetable explicitly.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.